Get started
Concept

Temsirolimus

OpenAlex ID: C2776820818
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 · Gary Hudes, Michael Carducci, et al. · New England Journal of Medicine · 3,692
Renal cell carcinoma
2017 · James J. Hsieh, Mark P. Purdue, et al. · Nature Reviews Disease Primers · 2,934
Targeting the PI3K pathway in cancer: are we making headway?
2018 · Filip Janku, Timothy A. Yap, et al. · Nature Reviews Clinical Oncology · 1,060
The mTOR Signalling Pathway in Human Cancer
2012 · Helena Pópulo, José Manuel Lopes, et al. · International Journal of Molecular Sciences · 867
PDF
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
2013 · Jiri Polivka, Filip Janku · Pharmacology & Therapeutics · 775
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
2005 · Evanthia Galanis, Jan C. Buckner, et al. · Journal of Clinical Oncology · 701
PDF
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
2009 · Georg Hess, Raoul Herbrecht, et al. · Journal of Clinical Oncology · 646
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
2005 · Thomas E. Witzig, Susan M. Geyer, et al. · Journal of Clinical Oncology · 513
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
2015 · Martin Dreyling, Wojciech Jurczak, et al. · The Lancet · 477
PDF
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 · Rodrigo Dienstmann, Jordi Rodon, et al. · Molecular Cancer Therapeutics · 476
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
2005 · Stephen Chan, Max E. Scheulen, et al. · Journal of Clinical Oncology · 471
PDF
Targeted Therapy for Metastatic Renal Cell Carcinoma
2006 · Robert J. Motzer, Ronald M. Bukowski · Journal of Clinical Oncology · 456
Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
2014 · Reshma Rangwala, Yunyoung C Chang, et al. · Autophagy · 441
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
2013 · Thomas E. Hutson, Bernard Escudier, et al. · Journal of Clinical Oncology · 413
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
2010 · Patricia Pérez-Galán, Martin Dreyling, et al. · Blood · 410
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
2011 · Amit M. Oza, Laurie Elit, et al. · Journal of Clinical Oncology · 353
PDF
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
2006 · Zhihong Zeng, Dos D. Sarbassov, et al. · Blood · 346
PDF
Strategies for the management of adverse events associated with mTOR inhibitors
2014 · Bruce Kaplan, Yasir Qazi, et al. · Transplantation Reviews · 332
PDF
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
2006 · Donatella Del Bufalo, Ludovica Ciuffreda, et al. · Cancer Research · 323
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
2006 · I Duran, J Kortmansky, et al. · British Journal of Cancer · 321
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
2012 · W-Y Shi, D Xiao, et al. · Cell Death and Disease · 312
PDF
Antileukemic activity of rapamycin in acute myeloid leukemia
2004 · Christian Récher, Odile Beyne-Rauzy, et al. · Blood · 310
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
2004 · S Chan · British Journal of Cancer · 303
PDF
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
2010 · T E Witzig, C B Reeder, et al. · Leukemia · 301
PDF
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
2017 · Rajen Mody, Arlene Naranjo, et al. · The Lancet Oncology · 288
Works count: 3,099
Citation count: 69,110
Year
Topic
Type